Results 231 to 240 of about 475,313 (268)

First Experience Using a Novel Variable Loop Catheter for Mapping and Pulsed Field Ablation of Atrial Fibrillation

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background and Aims A novel multielectrode variable loop catheter (VLC) has been introduced for atrial fibrillation (AF) ablation enabling 3D electroanatomic mapping and concomitant pulsed field ablation (PFA). This study sought to investigate the VLC under routine clinical conditions for AF ablation.
Thomas Fink, Vanessa Sciacca, Kevin Bannmann, Maximilian Moersdorf, Sebastian Beyer, Alessandro Parlato, Denise Guckel, Mustapha El Hamriti, Moneeb Khalaph, Martin Braun, Maxim Didenko, Guram Imnadze, Dominik Linz, Kevin Vernooy, Philipp Sommer, Christian Sohns   +15 more
wiley   +1 more source

Historical Development and Experience of Day Surgery in China: From the Perspective of Anesthesiologists

Pediatric Anesthesia, EarlyView.
ABSTRACT Background Day surgery has become the main mode of surgery in American and European countries, but it is still in the early stage in developing countries due to the limitation of medical technology and the backward management concept. At present, day surgery accounts for more than 60% of elective surgery in many countries in Europe and North ...
Jiangrong Luo, Chunbao Xie, Dan Fan
wiley   +1 more source

Efficacy and Safety of Direct Oral Anti‐Coagulants in Painful Venous Malformations in Children

Pediatric Dermatology, EarlyView.
ABSTRACT Direct oral anticoagulants (DOAC), including dabigatran, apixaban, and rivaroxaban, are increasingly used in adults for painful venous malformations (VMs) instead of subcutaneous drugs such as low molecular weight heparins or fondaparinux. However, these medications are poorly studied in children. In seven children with painful VMs and chronic
Olivia Boccara, Julie Bonigen, Véronique Soupre, Eve Puzenat, Annouk Bisdorff, Ludovic Drouet   +5 more
wiley   +1 more source

Women in space: A review of known physiological adaptations and health perspectives

Experimental Physiology, EarlyView.
Abstract Exposure to the spaceflight environment causes adaptations in most human physiological systems, many of which are thought to affect women differently from men. Since only 11.5% of astronauts worldwide have been female, these issues are largely understudied.
Millie Hughes‐Fulford, Danielle J. Carroll, Heather C. M. Allaway, Bonnie J. Dunbar, Aenor J. Sawyer   +4 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Venous thromboembolism

The Lancet, 2021
Venous thromboembolism, comprising both deep vein thrombosis and pulmonary embolism, is a chronic illness that affects nearly 10 million people every year worldwide. Strong provoking risk factors for venous thromboembolism include major surgery and active cancer, but most events are unprovoked.
F. Khan, T. Tritschler, S. Kahn, M. Rodger   +3 more
semanticscholar   +3 more sources

Venous thromboembolism

The Indian Journal of Pediatrics, 1999
Incidence of venous thromboembolism (VTE) in children is rapidly rising. Frequent use of central venous lines (CVLs) in children with a variety of disease processes has contributed to increased incidence of VTE. In addition, increased detection of VTE has been possible due to the availability of sensitive imaging studies such as Color Duplex/Doppler ...
Renuka Gera, Roshni Kulkarni
openaire   +5 more sources

Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis

Thorax, 2021
Background The prevalence of venous thromboembolic event (VTE) and arterial thromboembolic event (ATE) thromboembolic events in patients with COVID-19 remains largely unknown.
Boun Kim Tan, Sabine Mainbourg, A. Friggeri, L. Bertoletti, Marion Douplat, Y. Dargaud, C. Grange, H. Lobbes, S. Provencher, J. Lega   +9 more
semanticscholar   +1 more source

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Journal of Thrombosis and Haemostasis, 2020
Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients.
R. McBane, W. Wysokinski, J. Le-Rademacher, T. Zemla, A. Ashrani, A. Tafur, Usha Perepu, Daniel M. Anderson, Krishna Gundabolu, C. Kuzma, J. Perez Botero, Roberto A Leon Ferre, S. Henkin, C. Lenz, D. Houghton, P. Vishnu, C. Loprinzi   +16 more
semanticscholar   +1 more source

Venous Thromboembolism in Malignancy and Malignancy in Venous Thromboembolism

Pathophysiology of Haemostasis and Thrombosis, 1998
The activation of coagulation in patients with cancer contributes significantly to morbidity and mortality rates and may play a fundamental role in the host response to growing tumours. Patients with cancer are clearly at high risk for the development of venous thromboembolism (VTE), particularly during chemotherapy and surgery.
Frederick R. Rickles, Mark Levine
openaire   +2 more sources

Venous Thromboembolism

DeckerMed Medicine, 2020
Venous thromboembolism, which involves venous thrombosis and pulmonary embolism, is a leading cause of morbidity and mortality in hospitalized patients and is being seen with increasing frequency in outpatients. This chapter discusses the risk factors, etiology, classification, pathophysiology, natural history, prognosis, diagnosis (including venous ...
openaire   +1 more source